Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,340 INR | -1.42% | -5.98% | +7.48% |
May. 10 | Transcript : Cipla Limited, Q4 2024 Earnings Call, May 10, 2024 | |
May. 10 | Market Heavyweights Lifts Indian Equities to End Week Higher | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Weaknesses
- The firm trades with high earnings multiples: 26.21 times its 2024 earnings per share.
- With an enterprise value anticipated at 3.98 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.48% | 12.95B | B+ | ||
+19.62% | 43.27B | B- | ||
+24.52% | 22.92B | B+ | ||
+20.29% | 15.43B | - | ||
+42.51% | 11.83B | B | ||
-8.84% | 6.91B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+13.13% | 5.55B | B+ | ||
+9.14% | 4.9B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CIPLA Stock
- Ratings Cipla Limited